Trestle Biotherapeutics
Trestle Biotherapeutics is dedicated to developing bioengineered therapies for patients with kidney failure, aiming to create implantable tissues that can replace dialysis and delay transplantation. Their mission is to transform the lives of patients suffering from organ failure through innovative stem cell biology and 3D biofabrication technologies, bridging scientific disciplines and global expertise to advance regenerative medicine.
Industries
Nr. of Employees
small (1-50)
Trestle Biotherapeutics
Products
Implantable stem cell‑derived bioengineered kidney tissue (preclinical)
A preclinical-stage, stem cell-derived biofabricated tissue construct intended as an implantable therapeutic to restore renal function and reduce reliance on dialysis.
Implantable stem cell‑derived bioengineered kidney tissue (preclinical)
A preclinical-stage, stem cell-derived biofabricated tissue construct intended as an implantable therapeutic to restore renal function and reduce reliance on dialysis.
Services
Collaborative research agreements to explore integration of engineered vascular conduits with biofabricated kidney tissues to enable perfusion and vascularization.
Acquisition and commercialization of academic stem cell and biofabrication technologies via license agreements to support product development.
Collaborative research agreements to explore integration of engineered vascular conduits with biofabricated kidney tissues to enable perfusion and vascularization.
Acquisition and commercialization of academic stem cell and biofabrication technologies via license agreements to support product development.
Expertise Areas
- Bioengineered therapies for kidney disease
- Kidney organoid development
- Stem cell differentiation and reprogramming
- 3D biofabrication and bioprinting
Key Technologies
- 3D bioprinting (cellular extrusion)
- Organoid culture and maturation
- Pluripotent stem cell differentiation to renal lineages
- Automated high-throughput bioprinting
News & Updates
Trestle Biotherapeutics received a $1 million prize from the KidneyX Innovation Accelerator for their innovative approach in developing bioengineered kidney tissues for patients with kidney failure, aiming to replace dialysis and address the global organ shortage.
Trestle Biotherapeutics announced its participation in the Wellcome Leap HOPE program, a $50M initiative to bioengineer complex human organs and immune system interactions, aiming to develop bioengineered kidney tissues for patients with end-stage renal disease.
Trestle Biotherapeutics announced a research collaboration with Humacyte to explore technology synergies for bioengineering vascularized organs for transplantation, focusing on developing human bioengineered kidneys with vascular perfusion.
Trestle Bio announced a collaboration with Humacyte to explore potential avenues of technology integration for bioengineering vascularized organs, aiming to develop a human bioengineered kidney with vascular perfusion.
Trestle Biotherapeutics was highlighted by TechCrunch as one of the top biotech companies at Y Combinator’s W21 Demo Day, showcasing its innovative approach in regenerative medicine.
Trestle Biotherapeutics joined the Winter 2021 cohort of Y Combinator, receiving early financial investment and strategic support to accelerate its development of bioengineered kidney tissues.
Trestle Biotherapeutics received a $1 million prize from the KidneyX Innovation Accelerator for their innovative approach in developing bioengineered kidney tissues for patients with kidney failure, aiming to replace dialysis and address the global organ shortage.
Trestle Biotherapeutics announced its participation in the Wellcome Leap HOPE program, a $50M initiative to bioengineer complex human organs and immune system interactions, aiming to develop bioengineered kidney tissues for patients with end-stage renal disease.
Trestle Biotherapeutics announced a research collaboration with Humacyte to explore technology synergies for bioengineering vascularized organs for transplantation, focusing on developing human bioengineered kidneys with vascular perfusion.
Trestle Bio announced a collaboration with Humacyte to explore potential avenues of technology integration for bioengineering vascularized organs, aiming to develop a human bioengineered kidney with vascular perfusion.
Trestle Biotherapeutics was highlighted by TechCrunch as one of the top biotech companies at Y Combinator’s W21 Demo Day, showcasing its innovative approach in regenerative medicine.
Trestle Biotherapeutics joined the Winter 2021 cohort of Y Combinator, receiving early financial investment and strategic support to accelerate its development of bioengineered kidney tissues.